Register now to learn about a new option for relapsed or refractory follicular lymphoma

General Discussions

Immunotherapy Moves to SCLC, But Chemotherapy Is Still a Mainstay

By Beth Sandy, MSN, CRNP
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


Even with the addition of checkpoint inhibitors to the small cell lung cancer (SCLC) space, chemotherapy is still a mainstay, as the disease is highly sensitive to it, explains Beth Sandy, MSN, CRNP, a nurse at the Abramson Cancer Center of University of Pennsylvania.

Transcription

I don't think we're ever going to see us move away from chemotherapy in small cell [lung cancer]. But, the addition of immunotherapy to it has been an improvement.

The other part of it is that even though etoposide and platinum [-based drugs] seem to have really good response rates -- they do have really good response rates -- then we see in later lines of therapy, the chemotherapy is not working as well. So it's exciting to have another drug that's available in that setting.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.